Merlini Piera Angelica, Cugno Massimo, Rossi Marco L, Agricola Pietro, Repetto Alessandra, Fetiveau Raffaella, Diotallevi Paolo, Canosi Umberto, Mannucci Pier Mannuccio, Ardissino Diego
IV Division of Cardiology, Ospedale Niguarda, Milan, Italy.
Am J Cardiol. 2004 Apr 1;93(7):822-5. doi: 10.1016/j.amjcard.2003.12.017.
Thrombolytic therapy activates the contact system, and factor XII activation may activate the coagulation cascade and inflammation. It is not known whether an early inflammatory response is induced by thrombolytic therapy in patients with acute myocardial infarction (AMI). We prospectively measured the plasma levels of activated factor XII, cleaved kininogen, prothrombin fragment 1 + 2 (as indexes of the contact phase and coagulation activation), and interleukin-6 and C-reactive protein (CRP) (as indexes of inflammation) in 39 patients hospitalized for AMI within 12 hours of symptom onset: 26 receiving thrombolytic therapy and 13 heparin alone. Blood samples were collected at baseline and after 90 minutes and 24 hours. Patients undergoing thrombolysis had a significant early increase in activated factor XII (from 2.2 ng/ml at baseline to 4.7 ng/ml after 90 minutes; p = 0.0001), cleaved kininogen (from 26% to 37%; p = 0.001), and fragment 1 + 2 (from 1.4 to 2.1 nmol/L; p = 0.0001), whereas the 24-hour levels were similar to baseline levels. The levels of interleukin-6 significantly increased during the first 90 minutes (from 3.9 to 6.3 microg/ml; p = 0.001), and were even higher after 24 hours (11.9 ng/ml, p = 0.0001). CRP levels increased only after 24 hours (p = 0.0001). There were no changes in these parameters in patients receiving heparin alone, except for a 24-hour increase in interleukin-6 and CRP levels. Thus, in patients with AMI receiving thrombolytic therapy, early activation of inflammation parallels the activation of the contact system and the coagulation cascade, which might contribute to microvascular obstruction and reperfusion injury.
溶栓治疗可激活接触系统,而因子Ⅻ激活可能会激活凝血级联反应和炎症反应。目前尚不清楚急性心肌梗死(AMI)患者接受溶栓治疗是否会诱导早期炎症反应。我们前瞻性地测量了39例症状发作后12小时内入院的AMI患者血浆中活化因子Ⅻ、裂解激肽原、凝血酶原片段1+2(作为接触相和凝血激活的指标)以及白细胞介素-6和C反应蛋白(CRP)(作为炎症指标)的水平:26例接受溶栓治疗,13例仅接受肝素治疗。在基线、90分钟和24小时后采集血样。接受溶栓治疗的患者活化因子Ⅻ(从基线时的2.2 ng/ml增至90分钟后的4.7 ng/ml;p=0.0001)、裂解激肽原(从26%增至37%;p=0.001)和片段1+2(从1.4增至2.1 nmol/L;p=0.0001)早期显著升高,而24小时水平与基线水平相似。白细胞介素-6水平在最初90分钟内显著升高(从3.9增至6.3 μg/ml;p=0.001),24小时后更高(11.9 ng/ml,p=0.0001)。CRP水平仅在24小时后升高(p=0.0001)。仅接受肝素治疗的患者这些参数无变化,白细胞介素-6和CRP水平除外,其在24小时时升高。因此,在接受溶栓治疗的AMI患者中,炎症的早期激活与接触系统和凝血级联反应的激活平行,这可能导致微血管阻塞和再灌注损伤。